UB654
ProductTrastuzumab injection
Strength150mg/vial
IndicationsBreast cancer; Gastric cancer
TherapeuticsOncology
GMPCN - NMPA
RegistrationChina
ModalitiesAntibody
Exclusive Summary
- · Herceptin (Trastuzumab) biosimilar
- · Bringing new high-quality option for clinical anti-HER2 Treatment
- · The first commercial biologic of Oncology BU, got NMPA approval in 2023 Q1
我们能如何帮助您？
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →